StemCell Therapy

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Clinical Oncology Next Generation Sequencing market.

Trusted Business Insights presents an updated and Latest Study on Clinical Oncology Next Generation Sequencing Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Clinical Oncology Next Generation Sequencing market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Clinical Oncology Next Generation Sequencing Market Size Report 2025 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Clinical Oncology Next Generation Sequencing Market

The global clinical oncology next generation sequencing market size was estimated at USD 627.2 million in 2018. Significant increase in the adoption of genome-focused pharmacology for cancer treatment is expected to provide growth avenues for the market. NGS serves as one of the highly advanced genomic techniques for the analysis of mutations that lead to cancer progression.The growth of the market is supplemented by decrease in the cost of genetic sequencing, advancements in the field of personalized medicine and oncology, rise in prevalence of cancer, globally, and increase in adoption of this technique over single-gene testing. Since this technique is more reliable than Sanger sequencing for diagnosis, the market is expected to witness substantial growth over the forecast period.

Breakthrough advancements in the development of genetic-based tests for oncology and other disorders during the past few years have significantly propelled market growth. Next generation sequencing technology offers a better understanding of tumor mechanism, thus enabling rational drug design. As a result, more products are expected to get commercialized in the near future.A rise in oncology-related spending is further expected to fuel market growth in the coming years. Government organizations are focused on encouraging patients to regularly undergo diagnostic examinations to reduce oncology-related healthcare expenditures. As per data estimates, healthcare expenditure is anticipated to rise significantly, thereby influencing the adoption of NGS diagnostics platforms.The biotechnology industry is marked by high competition and so is the NGS market for clinical as well as research applications. Prominent participants are actively involved in R&D to develop novel rapid, small, and less expensive platforms. Service providers are embracing the trend of increasing the amount of constructed sequence reads for each cycle run.Commercially available sequencing platforms analyze both DNA and RNA samples. Key players aim to increase the utility of high throughput technologies for clinical applications. The acquisition of smaller entities operating in the market is also one of the strategic initiatives adopted by players to maintain a competitive position. For instance, in May 2018, Illumina acquired Edico Genome to accelerate data analysis for its next generation sequencing platforms.

Technology Insights of Clinical Oncology Next Generation Sequencing Market

Targeted sequencing in clinical oncology accounted for the largest revenue share in 2018 and is expected to maintain its share over the forecast period. Targeted sequencing and resequencing encompasses shortest read lengths and is one of the conventional forms of commercially available sequencing technology. Moreover, focused panels for targeted cancer sequencing aid in the reduction of cost burdens owing to reduction in the amount of data to be analyzed. As targeted cancer sequencing evaluates a limited gene-set, it can be used to analyze variations in rare tumor sub-clones with greater sensitivity and deep coverage.The whole-genome sequencing segment is expected to grow at the fastest rate through 2025. Application of whole genome sequencing technology for comparisons between tumor tissue and normal tissue in clinical oncology is attributive to segment growth. Developed rapid, large-capacity sequencers such as HiSeq and MiSeq series find application in largescale whole genome sequencing.Workflow InsightsNGS workflow includes library preparation, sample enrichment, sample quality assurance, DNA tagging, sequencing, DNA quantification, genetic data assemble, data storage and analysis, and interpretation. Sequencing accounted for the largest share in the clinical oncology NGS market as it is the most important and crucial step in the entire process and involves the usage of sophisticated platforms. Continuous R&D has led to the introduction of novel, benchtop, or portable NGS sequencing platforms, thereby complimenting market growth. Moreover, NGS platforms are expected to witness lucrative growth throughout the forecast period owing to the expected increase in adoption and usage rates of whole-genome sequencing.

Application Insights of Clinical Oncology Next Generation Sequencing Market

Next generation sequencing finds application in the field of clinical oncology for screening, companion diagnostics, and others. The adoption of NGS-based molecular diagnosis for oncology has increased as this technology allows concurrent sequencing of several target genes and provides rich diagnostic markers for the development of molecular diagnostic assays.Application of NGS technology in the field of oncology ensures early diagnosis so that treatment measures can be taken in time. Therefore, the arrival of NGS for cancer diagnosis has opened many new frontiers in the field. For instance, large-scale projects such as International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) have issued data from thousands of tumors across major cancer types. This data can be used to have a comprehensive overview of cancerous cells and help enhance prognostic and therapeutic applications.The market for companion diagnostics is expected to grow significantly in the coming years owing to numerous benefits offered by the technique in the field of oncology. Currently, available companion diagnostic products are applicable for non-small cell lung cancer, melanoma, colorectal, ovarian, and breast cancers.End-use InsightsBy way of end use, the clinical oncology next generation sequencingmarket has been segmented into hospitals, clinics, and laboratories. Laboratories held a prominent share in the market for clinical oncology NGS and this trend is likely to continue over the forecast period. The hospitals segment is expected to register a significant CAGR through 2025. Rise in adoption of NGS services in hospitals to determine the rate of disease progression and scale-up the appropriate treatment regimen for cancer is anticipated to influence growth in this segment.

Provision of clinical services by leading players in the market such as Illumina, which includes CLIA certified tests for predisposition screening, is anticipated to boost revenue in the coming years. Clinics utilize NGS technology to identify novel cancer mutations, for genetic testing for hereditary cancer syndrome, for personalized oncology treatment, and for detection of circulating DNA for cancer.

Regional Insights of Clinical Oncology Next Generation Sequencing Market

North America occupied the largest share in the global market in 2018 owing to increased focus of government bodies on cancer treatment, rise in healthcare expenditure, and presence of adequate healthcare infrastructure. Moreover, high prevalence of cancer, growing demand for personalized medicine, well-developed healthcare facilities, and availability of novel diagnostics techniques, especially in the field of oncology, can be attributed to the estimated market share of the region. Additionally, growing morbidity and mortality due to cancer has increased the need for development of novel therapies, thereby driving this regional market.Asia Pacific is expected to be the fastest-growing region throughout the forecast period majorly due to continuous reforms in the healthcare and pharmaceutical industries in the region. Other factors contributing to this growth are untapped markets in emerging economies. The market is continuously driven by rise in cancer incidence across Asia Pacific. China dominates the cancer burden in the region, followed by India, Japan, Indonesia, and the Republic of Korea. The top three types of cancer with his incidences in the region are breast, lung, and prostate cancer.

Market Share Insights of Clinical Oncology Next Generation Sequencing Market

The global market is marked by the presence of high competition among market players. Illumina and Roche account for a substantial share owing to wide product offerings in the field of next-generation sequencing for cancer. Other prominent players operating in this market space include Agilent; Thermo Fisher Scientific; Myriad Genetics; Beijing Genomics Institute (BGI); Perkin Elmer, Inc.; Qiagen NV; Partek, Inc.; Pacific Bioscience, Inc.; Foundation Medicine; Oxford Nanopore Technologies Ltd.; Paradigm Diagnostics, Inc.; Caris Life Sciences; and Eurofins Scientific.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Clinical Oncology Next Generation Sequencing Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, this market research report has segmented the globalclinical oncology next generation sequencing market report on the basis of technology, workflow, application, end use, and region:

Technology Outlook (Revenue, USD Million, 2019 2030)

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing

Workflow Outlook (Revenue, USD Million, 2019 2030)

NGS Pre-Sequencing

NGS Sequencing

NGS Data Analysis

Application Outlook (Revenue, USD Million, 2019 2030)

Screening

Sporadic Cancer

Inherited Cancer

Companion Diagnostics

Others

End-use Outlook (Revenue, USD Million, 2019 2030)

Hospitals

Clinics

Laboratories

Quick Read Table of Contents of this Report @ Clinical Oncology Next Generation Sequencing Market Size Report 2025 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Originally posted here:
How COVID-19 Pandemic Will Impact Clinical Oncology Next Generation Sequencing Market Business Opportunity, And Growth 2020-2026 - Cole of Duty

A research team led by Francesca Luca, Ph.D., associate professor of Wayne State Universitys Center for Molecular Medicine and Genetics, has published a study that annotated environmental components that can increase or decrease disease risk through changes in gene expression in 43 genes that could exacerbate or buffer the genetic risk for cardiovascular disease. Their results highlight the importance of evaluating genetic risk in the context of gene-environment interactions to improve precision medicine.

Interpreting Coronary Artery Disease Risk Through GeneEnvironment Interactions in Gene Regulation was published in Genetics, the journal of the Genetics Society of America.

The study, said Dr. Luca, also of the WSU Department of Obstetrics and Gynecology, illustrates that combining genome-wide molecular data with large-scale population-based studies is a powerful approach to investigate how genes and the environment interact to influence risk of cardiovascular disease.

By identifying regions of DNA important for endothelial cell response to different common environmental exposures, the researchers discovered that caffeine can influence the risk of cardiovascular disease. The study demonstrates the potentially beneficial and/or detrimental effects of certain environmental exposures on the cardiovascular disease risk differ depending on individual DNA sequence.

The study focused on cardiovascular disease, Dr. Luca said, because it is the leading cause of death, both in the United States and worldwide. Also, the disease is highly multifactorial, with large contributions from both environmental and genetic risk factors. By treating endothelial cells under a controlled environment, we can discover how these genetic and environmental risk factors influence each other at the molecular level, she said. Our lab has developed expertise in cardiovascular research, with additional projects using endothelial cells to develop new assays to test the regulatory activity of genetic variants. The approach outlined in this paper can be applied to many different diseases; for example, our lab has also focused on how bacteria in the human gut affect gene expression in the colon, and also on the effect of psychosocial stress on asthma.

While the work identified regions of the genome important for how endothelial cells respond to the environment and can influence the risk of cardiovascular disease, the researchers do not yet know exactly which genetic variants are directly responsible. A former graduate student, Cynthia Kalita, developed an assay to test thousands of genetic variants for gene regulatory activity. The researchers can test the variants discovered in their study using that assay to validate and explore the mechanisms by which they exert their effects, Dr. Luca said. They also are developing computational/statistical methods that can yield better personalized risk scores.

We have extended our approach to study cardiomyocytes, which are the muscle cells of the heart. Healthy heart tissue is difficult to obtain, so we have collaborated with researchers at the University of Chicago to derive cardiomyocytes from stem cells, Dr. Luca said. This will allow us to shift our focus from the vasculature to the heart itself, where we can study diseases like cardiomyopathies and arrhythmias.

As the cost of DNA sequencing continues to decrease, Dr. Luca expects that genetic testing will play a greater role in preventive health care. To fully realize the potential of precision medicine, we need to consider both genetic and environmental risk factors of disease, and how they interact. While there are already direct-to-consumer tests that prescribe an individualized diet based on DNA, these products currently offer no demonstrated clinical value. However, with very large numbers of individuals for whom we have both DNA sequencing and information on diet and lifestyle, we may one day be able to offer better recommendations.

Others involved in the study included Anthony Findley, an M.D./Ph.D. student; Allison Richards, Ph.D., a research scientist; Cristiano Petrini, of the Center for Molecular Medicine and Genetics; Adnan Alazizi, lab manager; Elizabeth Doman, of the Center for Molecular Medicine and Genetics; Alexander Shanku, Ph.D., research scientist; Gordon Davis, of the Center for Molecular Medicine and Genetics; Nancy Hauff, Department of Obstetrics and Gynecology; Yoram Sorokin, M.D., professor of Obstetrics and Gynecology; Xiaoquan Wen, of the Department of Biostatistics at the University of Michigan; and Roger Pique-Regi, Ph.D., associate professor of the Center for Molecular Medicine and Genetics, and of the Department of Obstetrics and Gynecology.

Link:
Researchers identify environmental components that affect gene expression in cardiovascular disease - The South End

Precision Medicine Market Size was valued around USD 50 billion in 2018 and is expected to witness lucrative growth from 2019 to 2025.

Rising demand and advancements in cancer biology will augment personalized medicine market during the forecast timeframe. Development of novel genetic technologies that discovers the functional effect of genetic information that leads in developing cancer, thus, should propel huge demand for cancer biology. However, the high price associated with usage of precision medicine may restrict the precision medicine market growth over forecast period.

Download the sample report to understand the market growth in Precision Medicine Market:

https://www.insidemarketreports.com/sample-request/9/137670/precision-medicine-markets

On the basis of technology the precision medicine market is segregated into big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics. Rising focus of competitors on producing advanced drugs leading to better treatment for several chronic diseases will drive drug discovery segmental growth. Similarly, rising incidence of chronic as well as respiratory diseases will drive the growth of the market.

Precision medicine market by application is further divided into oncology, immunology, central nervous system (CNS), respiratory diseases. Increasing prevalence of cancer cases and usage of precision medicine in development of new drugs will increase the oncology segmental market growth. Similarly, increasing demand for bioinformatics and big data analytics to set apart human genome data secured from immunological processes augment segmental growth.

On the basis of end users, the precision medicine market is further divided as pharmaceutical companies, diagnostic companies, healthcare IT companies. Rising demand for producing novel tools for rapid integration, storage, and analysis of patient information will drive the business growth.

North America is anticipated to account for the largest share of the Global Precision Medicine Market. Increasing prevalence of cancer across the U.S will augment the growth of the precision medicine market. Similarly, rising healthcare expenditure will drive the growth of precision medicine market over the forecast period. Asia-Pacific is expected to show rapid growth in coming years owing to growing number of investments in R&D activities.

By Technology

By Application

By End users

By Region

Company Coverage

Conclusion:

In this report, we had discussed the market situation of Precision Medicine Market. As we know the world is going to be tech savvy, the demand of trending products and technologies is also increasing. This report can help to understand the business growth in the Precision Medicine Market and new opportunities at new places.

The only person you are destined to become is the person you decide to be!!

Hurry up! and grab the discount for this report

https://www.insidemarketreports.com/discount/9/137670/precision-medicine-markets

For any type of research report, Contact us at:

Company Name: Inside Market Reports

Address: 1 Apache Way, Westford, Massachusetts 01886, USA

Email: [emailprotected]

Contact no: +1-617-230-0741

Go here to read the rest:
Global Precision Medicine Market Growth From 2019 to 2025- Market Report, Insights Analysis And Opportunities - Cole of Duty

REDMOND, Wash. June 18, 2020 On Thursday, Microsoft Corp. and Johns Hopkins Medicine (JHM) announced a five-year relationship centered on Microsofts Azure and analytical tools that will support new discoveries as part of JHMs inHealth precision medicine initiative. The work will bring together JHMs leading global research expertise with the power of Microsoft Azure, and its AI capabilities, to help advance JHMs discoveries that will benefit personalized health care. JHM will maintain total control over its data.

inHealth embodies Johns Hopkins commitment to precision medicine, using new tools to understand and manage patients health, informed by their broader health history and environment. This program integrates JHMs longstanding leadership in health care research and delivery with the expertise of the Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Whiting School of Engineering and Johns Hopkins University Applied Physics Lab.

In support of inHealth, JHM has established 16 Precision Medicine Centers of Excellence, where researchers are pursuing breakthroughs in numerous disease settings, such as prostate cancer and multiple sclerosis. JHM aims to have 50 centers in the next five years.

Ad StatisticsTimes Displayed: 1049244Times Visited: 9191

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Ethical use of patient data is a cornerstone of all of JHMs partnerships with patients, including this important work with Microsoft in precision medicine. All projects are compliant with all appropriate privacy regulations, and JHM maintains strict control over all data, including through the use of its Institutional Review Board and its internal Data Trust Council that reviews data use across JHM.

It is a distinct privilege to partner with many of the worlds leading physicians, scientists and engineers at JHM as they use Microsoft Azure and its AI and machine learning capabilities to support some of the most advanced research and breakthroughs in precision medicine, said Gregory Moore, M.D., Ph.D., corporate vice president of Microsoft Health. Im inspired by the collaboration and its bold goals to improve health for all by bringing together some of the worlds best minds in medicine and technology to deliver the future of medical science innovation.

JHM has previously used Microsoft services as JHM developed its pioneering Precision Medicine Analytics Platform (PMAP), a highly innovative data platform that allows collection and analysis information from a broad array of sources in a secure environment. This new agreement will enable inHealth to expand use of other Microsoft resources, such as advanced services, AI, machine learning and analytics.

More information about Johns Hopkins Medicine precision medicine work and inHealth can be found here.

Microsoft (Nasdaq MSFT @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.

More here:
Microsoft Azure will become the preferred cloud platform for Johns Hopkins in Health precision medicine initiative - DOTmed HealthCare Business News

By Kevin Brown

Precision radiation medicine is a twenty-first century approach to fundamental cancer therapy. Approximately 50-60 percent of cancer patients will receive radiation therapy at some point during their cancer journey, as it is used for curative regimens and palliative care. Radiation therapy has been a pillar of cancer treatment for most of the past century, yet far from being an old or unsophisticated technology, recent advances in radiation delivery technology and software automation have enabled a new era of personalized precision radiation medicine.

The ability to develop personalized radiation therapy regimens is a direct result of the increased precision and accuracy with which cutting-edge systems deliver radiation doses. These systems enable delivery of higher doses of radiation to tumors, which increases efficacy, while reducing exposure of normal tissue, which is essential for improving safety, tolerability and long-term toxicity. The improved targeting to tumors allows more radiation to be delivered during each treatment session, which results in fewer sessions, reduces patients treatment burden, and allows more patients to be treated on each delivery system. Importantly, improved targeting is also opening the door to the use of radiation therapy in hard-to-treat cancers that are not amenable to traditional radiation therapy approaches.

Ad StatisticsTimes Displayed: 1049244Times Visited: 9191

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

The challenges of cancer care during the Covid-19 pandemicThe Covid-19 pandemic presents unique and diverse challenges to the safe and effective delivery of cancer care. A key challenge is that many cancer therapies, including chemotherapy and some targeted therapies, are immunosuppressive. Patients treated with these therapies have an increased risk of infection in routine treatment, and these regimens put patients at high risk of infection with SARS-CoV-2, the virus that causes Covid-19. The curtailing of non-emergency surgeries at most hospitals and cancer care centers is also upending standard of care cancer regimens that include surgery.

Link:
Precision radiation medicine and Covid-19: Providing optimal outcomes during extraordinary times - DOTmed HealthCare Business News

NEW YORK, June 18, 2020 /PRNewswire/ --

INTRODUCTIONHarnessing the naturally evolved, medicinal functions of gut bacteria in order to achieve desired clinical outcomes / bene?ts is the core principle behind the rapidly growing field of microbiome therapeutics. In fact, in recent years, promising insights from microbiome focused research has been the cause of much enthusiasm within the medical science community, offering a novel perspective related to personalized medicine. , This particular class of products exists at the interface of naturopathic remedies (considering the active substances that are currently used) and clinically validated interventions, having demonstrated the ability to offer legitimate, quantifiable clinical benefits. Around 200 companies, including both private and public stakeholders, claim to be currently engaged in developing microbiome-based therapies for the treatment of a wide range of diseases. Several large pharmaceutical companies have also demonstrated interest in partnering with early-stage innovators in this domain. , Having said that, most such initiatives are either still in the preclinical stages or early phase clinical trials. There are a few microbiome-based product candidates in phase II/III trials, which are anticipated to drive the market's growth in the short-mid term. According to our estimates, the microbiome-based therapeutics market is projected to be worth over USD 1.5 billion by 2030, growing at an annualized rate of over 30%.

Read the full report: https://www.reportlinker.com/p05915359/?utm_source=PRN

Despite the evident increase in interest in this field, manufacturing live microbial therapeutics remains a largely unaddressed area of concern. In fact, experts believe that the lack of sufficient manufacturing capacity is one of the major impediments to the commercialization of such products. Other challenges include absence of the required industry standards related to manufacturing live biotherapeutics, reproducibility (batch-to-batch consistency) related concerns, lack of expertise and infrastructure to handle anaerobic microbial strains, scaling up existing manufacturing protocols, intellectual property related issues (existing patent law prohibits patenting live organisms and naturally occurring materials) and uncertainties related to regulatory review and product approval. Owing to the aforementioned reasons and several others, such as need for specialized facilities, equipment and operational expertise, innovator companies have begun relying on contract manufacturers for their microbiome-related development and production needs. Outsourcing is known to offer several benefits, which include reductions in capital investment, access to larger production capacities, expediting time-to-market, and commercial risk handling and mitigation (to a significant extent). Presently, a number of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) claim to offer services for manufacturing microbiome-related products. In fact, some have even developed end-to-end capabilities, starting from drug development to regulatory filings, and commercial scale production, in this field.

SCOPE OF THE REPORTThe "Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030" report features an extensive study of the current landscape and future opportunities related to contract services for microbiome therapeutics. The study features an in-depth analysis, highlighting the capabilities of a diverse set of contract service providers, including CMOs and CDMOs. Amongst other elements, the report includes: A detailed review of the overall landscape of companies offering contract services for manufacturing of microbiome therapeutics, including information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, filtration, lyophilization, fill / finish, cell banking, and analytical services), type of product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of therapeutic (prebiotics and probiotics), type of drug molecule (small molecules and biologics / live biotherapeutics (LBPs)), type of fermentation (aerobic and anaerobic), type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), injectables and others), type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), number and location of manufacturing facilities (country-wise), facility size (if available), as well as their certifications, and company's contact details. A list of companies with in-house manufacturing facilities for microbiome therapeutics along with information on year of establishment, company size, scale of operations (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities (country-wise). Elaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome therapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities (if available), and recent developments and an informed future outlook. An informative, regional capability analysis of microbiome contract manufacturers based on supplier strength (which takes into account a company's size and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities), which provides a means to stakeholders for identifying ways to gain a competitive edge in the industry. A list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account the company's size and its experience in this field), company's pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and the availability of in-house manufacturing capabilities. A detailed clinical trial analysis of more than 150 completed, ongoing and planned studies of various microbiome therapeutics sponsored by both industry and non-industry players; it highlights prevalent trends across various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, trial recruitment status, study design and trial focus, highlighting leading sponsors (in terms of number of trials conducted), type of organization, popular therapeutic areas, and regional distribution of trials. An estimate of the overall, installed capacity for manufacturing of microbiome therapeutics, taking into consideration the capabilities of various stakeholders, based on data gathered via secondary and primary research; it presents the distribution of available capacity in terms of quantity of microbiome therapeutics produced (in liters, per year), across important market segments, such as company size (small-sized, mid-sized and large companies), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe and Asia-Pacific and rest of the world). An informed estimate of the annual clinical demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players. A qualitative analysis, highlighting the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. An analysis of potential market roadmaps and detailed discussion, highlighting various short-term and long-term strategies that can be adopted by microbiome contract manufacturers, in order to expand their respective businesses over the coming years. A review of the varied microbiome-focused initiatives of big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the microbiome therapeutics contract manufacturing market. Based on multiple parameters, such as projected growth of the overall microbiome therapeutics market, cost of goods sold and direct manufacturing costs, we developed informed estimates describing the financial evolution of the market, over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of product manufactured (API and FDF), [B] type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), [C] type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), [D] company size (very small / small-sized, mid-sized and large / very large), [E] scale of operation (preclinical, clinical and commercial), and [F] key geographical regions, covering North America, Europe, Asia-Pacific, and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.The opinions and insights presented in this study was influenced by inputs solicited via a survey and discussions held with multiple senior stakeholders in the industry. The report features detailed transcripts of discussions held with the following individuals: Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic) Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals) Assaf Oron (Chief Business Officer, BiomX) Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies) Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories) JP Benya (Vice President, Business Development, Assembly Biosciences) Rob van Dijk (Business Development Manager, Wacker Biotech) Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include: Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts' viewsWhile the focus has been on forecasting the market till 2030, the report also provides our independent view on technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINESChapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the microbiome therapeutics contract manufacturing market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to the human microbiome, along with information on the various types of microbiome therapeutics. It also features an elaborate discussion on the functions of the microbiota, emphasizing on the key insights generated from the Human Microbiome Project (HMP). Further, the chapter also includes a description of the various steps that are involved in the manufacturing of microbiome therapeutics. In addition, it highlights the challenges associated with manufacturing such products and the growing need for outsourcing in this domain. Finally, it provides a list of key factors that need to be considered by innovator companies while selecting a CMO partner.

Chapter 4 provides an overview of the microbiome contract manufacturing landscape. It includes information on over 40 contract manufacturers that claim to offer microbiome therapeutics manufacturing services. In addition, it features an in-depth analysis of these companies, based on a number of parameters, such as on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, filtration, lyophilization, fill / finish, cell banking, and analytical services), type of product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of therapeutic (prebiotics and probiotics), type of drug molecule (small molecules and biologics / live biotherapeutics (LBPs)), type of fermentation (aerobic, anaerobic, and genetically modified organisms), type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), injectables and others), type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), number and location of manufacturing facilities (country-wise), facility size (if available), as well as their certifications, and company's contact details. A list of companies with in-house manufacturing facilities for microbiome therapeutics along with information on year of establishment, company size, scale of operations (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities (country-wise).

Chapter 5 includes detailed profiles of key industry players (large and mid-sized companies established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome therapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities (if available), and recent developments and an informed future outlook

Chapter 6 features an informative regional capability analysis of microbiome contract manufacturers based on supplier strength (which takes into account a company's size and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities), which provides a means to stakeholders for identifying ways to gain a competitive edge in the industry.

Chapter 7 features a list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account a company's size and its experience in this field), company's pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and the availability of in-house manufacturing capabilities.

Chapter 8 provides a detailed clinical trial analysis of more than 150 completed, ongoing and planned studies of various microbiome therapeutics sponsored by both industry and non-industry players; it highlights prevalent trends across various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, trial recruitment status, study design and trial focus, highlighting leading sponsors (in terms of number of trials conducted), type of organization, popular therapeutic areas, and regional distribution of trials.

Chapter 9 features an estimate of the overall, installed capacity for manufacturing of microbiome therapeutics, taking into consideration the capabilities of various stakeholders, based on data gathered via secondary and primary research; it presents the distribution of available capacity in terms of quantity of microbiome therapeutics produced (in liters, per year), across important market segments, such as company size (small-sized, mid-sized and large companies), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe and Asia-Pacific and rest of the world).

Chapter 10 features an informed estimate of the annual clinical demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.

Chapter 11 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 12 features an analysis of potential market roadmaps and detailed discussion, highlighting various short-term and long-term strategies that can be adopted by microbiome contract manufacturers, in order to expand their respective businesses over the coming years.

Chapter 13 a review of the varied microbiome-focused initiatives of big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.

Chapter 14 features an elaborate market forecast analysis, highlighting the likely growth of microbiome contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of product manufactured (API and FDF), [B] type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), [C] type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), [D] company size (very small / small-sized, mid-sized and large / very large), [E] scale of operation (preclinical, clinical and commercial), and [F] key geographical regions, covering North America, Europe, Asia-Pacific, and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.Chapter 15 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 16 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic), Gaurav Kaushik (Managing Director and Chief Executive Officer, Meteoric Biopharmaceuticals), Assaf Oron (Chief Business Officer, BiomX), Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies), Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories), JP Benya (Vice President, Business Development, Assembly Biosciences), Rob van Dijk (Business Development Manager, Wacker Biotech), and Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical).

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 18 is an appendix, which contains the list of companies and organizations mentioned in the report.

Chapter 19 is an appendix, which contains the list of companies that claim to offer contract manufacturing for probiotic supplements.

Read the full report: https://www.reportlinker.com/p05915359/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read more from the original source:
Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms,...

SAN FRANCISCO--(BUSINESS WIRE)--IncellDx announces the patent filing with the USPTO and the Pre-EUA with the FDA for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of a novel coronavirus disease 2019 (COVID-19), is now a global pandemic. Growing information has demonstrated that a dysregulated and/or hyper-immune response causes a cytokine storm with massive increases in cytokines and chemokines which leads to infiltration of immune cells in multiple organs driving the significant co-morbidity and mortality in severe COVID-19. CCL5/RANTES is a chemokine that binds to the chemokine receptor CCR5. CCR5 is expressed on immune cells such as T-lymphocytes, macrophages, and NK cells. CCL5/RANTES acts like a magnet for these cells expressing CCR5. Thus CCL5/RANTES is a marker for the early stages of immune dysregulation in COVID-19 and as a possible therapeutic marker to determine when and how long therapy targeting CCR5 or RANTES should be continued. Other Cytokines included in the COVID-19 Cytokine Panel can be used to monitor other COVID-19 therapeutic approaches targeting other cytokines involved in the cytokine storm.

Dr. Bruce Patterson, chief executive officer of IncellDx, commented, When we were developing a cytokine quantification assay for possible COVID trials in China, we discovered that infected patients had consistently high levels of CCL5/RANTES in plasma which in some cases was 100 times normal depending on the severity of the disease. Other reports in the literature demonstrated that CCL5/RANTES can be elevated in renal failure, liver failure, coagulopathies, and in Kawasakis disease, all co-morbidities seen in COVID-19. Therapies targeting CCR5 are currently in trials against COVID-19 and we are extremely excited about filing an initial inquiry with the FDA concerning the potential use of a battery of companion tests to monitor the efficacy of drugs in the fight against this virus. It makes sense that we have diagnostics for the presence or absence of virus, exposure to the virus, and the next round of diagnostics should be personalized medicine approaches to determining the efficacy of COVID-19 therapies.

Dr Patterson is the primary author of the pre-print Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19 currently undergoing peer review.

Company files Pre-EUA with FDA for CCR5 receptor occupancy and a COVID cytokine panel including IL-6, IL-8,TNF-a, GM-CSF, and CCL5/RANTES.

Here is the original post:
IncellDx Files Patent for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19 and Other Cytokine Storm Conditions -...

With the rapid technological breakthrough, personalized medicine is gaining popularity. Personalized medicine is rapidly evolving healthcare, in which the genetic profile of an individual is used to customize health management. Next-Generation Sequencing (NGS) is a state-of-the-art technology that has revolutionized genetic studies. This approach is transforming medicine by providing individuals a genetic profile that guides decisions made regarding the prevention, diagnosis, and treatment of disease; this both maximizes health benefits and minimizes the risk of disease. This technology is becoming more common in oncology, though the clinical benefit of incorporating it into precision medicine strategies remains under significant debate. The speed, accuracy, and increasing affordability of NGS have aided the introduction of precision medicine, which involves designing treatment based on a persons disease-driving molecular alterations. Several studies have shown the utility of NGS in identifying clinically actionable mutations in cancer patients. For example, the Genomics Evidence Neoplasia Information Exchange (GENIE), an international data-sharing consortium, estimated an actionability rate of 30% across numerous cancers. Moreover, rising cancer burden has led to the growth in R&D in this field.

Download Sample of This Strategic Report https://univdatos.com/request_form/form/244

Insights Presented in the Report

Browse Complete Summary of This Report https://univdatos.com/report/next-generation-sequencing-for-personalized-cancer-medicine-market-current-scenario-and-forecast-2020-2026

Reasons to buy this report:

Feel free to contact us for any queries https://univdatos.com/request_form/form/244

Customization Options:

NGS in Personalized Cancer Medicine market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

About Us:

UnivDatos Market Insights (UMI), is a passionate market research firm and a subsidiary of Universal Data Solutions. Rigorous secondary and primary research on the market is our USP, hence information presented in our reports is based on facts and realistic assumptions. We have worked with 200+ global clients, including some of the fortune 500 companies. Our clientele praises us for quality of insights, In-depth analysis, custom research abilities and detailed market segmentation.

Contact us:

UnivDatos Market Insights (UMI)

Email: [emailprotected]

Web: https://univdatos.com

Ph: +91 7838604911

Read this article:
Research Report on Next-Generation Sequencing for Personalized Cancer Medicine Market Size & Share 2020 With Top Players and COVID-19 Analysis and...

According toBlueWeave Consultingthe globalAI in Healthcare marketis estimated to reach US$ 37.9 Billion by 2026 with a growing CAGR of 52.3 % during the forecast period 2020- 2026. Several factors driving growth are the increasing need to reduce healthcare costs, rising importance of big data in healthcare, increased acceptance of precision medicine and raising hardware costs. Increasing applicability of AI-based software in medical care and growing investment in venture capital can also be attributed to the surge in demand for this technology. For example, Care Predict, Inc. is using AI technology to track changes in behavioral patterns and activity to predict health issues early.

Request to get the report sample pages at :https://www.blueweaveconsulting.com/ai-in-healthcare-market-bwc19396/report-sample

Increasing number of cross-industry partnerships are expected to boost the healthcare sectors adoption of AI, which is further responsible for its lucrative growth rate. GNS Healthcare entered into a cross-industry partnership with Alliance and Amgen in September 2018 to conduct oncology clinical trials. The goal of the collaboration was to use data from clinical trials and Artificial Intelligence (AI) to identify factors that improve treatment responses in patients with metastatic colorectal cancer (CRC).

AI adoption in healthcare is increasing, with an increased focus on improving patient care quality through the use of artificial intelligence in various aspects of healthcare services, such as virtual assistants & surgeries. The AI-based technologies, such as clinical decision support systems & voice recognition software, help streamline hospital workflow procedures, and optimize medical care, thus improving patient experience. Incorporating AI into healthcare has multiple advantages for both patients and healthcare providers. AI, such as, allows personalized treatment, based on health conditions and past medical history. In addition, AI-based software can be used for continuous health monitoring, which in effect can ensure prompt care & treatment and may ultimately decrease hospital stay. On the other side, medical practitioners unwillingness to adopt new technology, a drastic lack of predetermined and uniform regulatory guidelines, a shortage of curated health care data and data privacy issues impede the markets potential to attain higher grounds.

AI-enabled bots are an AI program that patients can communicate with on a website or by telephone via a chat window. Applications such as scheduling appointments; reviewing insurance coverage parameters; quick access to information on drug interactions and side effects; collecting up-to-date information on patient medications, health care staff and recent procedures; designing special diet strategies for nutritional limited patients; and contacting discharged patients to follow up on treatment plans and ads. Such technologies are expected to lead the growth of hospital and inpatient care systems. Furthermore, the growing need for accurate & early diagnosis of chronic diseases and disorders further supports this markets growth. Nevertheless, the reluctance to implement AI technologies among end-users, lack of trust and potential risks associated with AI in the healthcare sector somewhat restrict the growth of this market.

Application for patient management to see significant growth in the market with significant pace in coming years as successful patient management is one of the most important needs for hospital facilities. Several studies have shown how important patient participation is in improving health outcomes. Lack of such participation contributed greatly to preventable deaths. Smart wearables also play a crucial role in transforming the current healthcare sector. Consumers are also becoming more aware of wearables, and many consumers today believe that wearing a smart device that monitors their vitalities will lead to increased average life expectancy.

Request to get the report description pages at :https://www.blueweaveconsulting.com/ai-in-healthcare-market-bwc19396/

Artificial intelligence in healthcare market is fragmented owing to the presence of number of large-sized companies, mid-sized & small-sized companies, and many start-ups that provide artificial intelligence in healthcare industry. However, the companies that hold the majority share of artificial intelligence in healthcare market are NVIDIA, Intel, IBM, Microsoft, Google, Siemens Healthineer, General Electric (GE) Company, Medtronic, Amazon Web Services (AWS), Koninklijke Philips, Johnson & Johnson Services, Butterfly Network, Welltok, Inc., Micron Technology and Other Prominent Players.

About Us

BlueWeave Consultingis a one-stop solution for market intelligence regarding various products and services online & offline. We offer worldwide market research reports by analyzing both qualitative and quantitative data to boost up the performance of your business solution. BWC has built its reputation from the scratches by delivering quality performance and nourishing the long-lasting relationships with its clients. We are one of the promising digital market intelligence generation company delivering unique solutions for blooming your business and making the morning, more rising & shining.

Contact Us:

[emailprotected]

https://www.blueweaveconsulting.com

Global Contact: +1 866 658 6826,+1 425 320 4776

Read the original:
AI in Healthcare Market projected a CAGR of 52.3% during the forecast period, 2020-2026 - 3rd Watch News

MANOA A new study out of the University of Hawaii at Manoa suggests reef health may largely be dictated by a microscopic turf war between coral and algae, though other environmental factors still impact reefs, such as ocean acidification or excess nutrients.

The study, published in the journal PNAS, was led by researchers at UH and San Diego State University, and found that the outcome of the competition between coral and turf algae is determined by the assemblage of microbes at the interface where the contenders meet, according to a UH press release.

In the release, researchers explain all plants and animals are associated with communities of viruses and microbes their microbiome that interact via a suite of chemicals produced by their metabolism, termed metabolites.

The study investigated the role of each component, host organisms, viruses, bacteria and metabolites, in coral-turf algal interactions. The researchers gathered data on genes, proteins and metabolic products associated with corals and algae on a reef and directly looked at the bacteria and viruses under a microscope.

We found that when coral interacts with turf algae on a reef, there is a unique chemical and bacterial community that forms at the interface between these two organisms, an emergent microbiome, said Ty Roach, postdoctoral researcher at the Hawaii Institute of Marine Biology in the UH School of Ocean and Earth Science and Technology and co-lead author of the study.

This interface community is made up of larger bacterial cells that use energy at a faster rate. Our data suggest that this change in bacterial size and energy use, which can negatively affect coral, is driven by a change in which types of bacteria dominate the microbiome.

Co-lead author Mark Little, a doctoral candidate at SDSU, explained that chemical analysis indicates the change is driven by bacteria that feed on algal-derived biochemicals, a phenomenon called the algal feeding hypothesis.

Interestingly, these changes in bacterial groups and their energy use, which come from feeding on specific chemicals, are similar to changes seen in the human gut, with dominant bacteria linked to obesity, Little said.

Coral reefs are valued for their cultural and ecological importance, providing protection against storms and waves, and serve as reservoirs of biodiversity. Restoring coral cover and building reef resilience provides the foundation essential to a functional and healthy reef ecosystem, which is critical for the surrounding community.

This highlights the fact that many ecological interactions between organisms are actually mediated by viruses and bacteria, said Forest Rohwer, biology professor at SDSU and senior author of the study. This provides opportunities to engineer probiotics to alleviate the effects of stressors on corals.

The research team plans to use the insight gained from this study to design and test probiotic blends for use on corals. In this way, they aim to utilize personalized-medicine techniques to help corals gain an ecological advantage over competitors such as harmful algae.

Jessica Else, editor-in-chief, can be reached at 245-0457 or jelse@thegardenisland.com.

Read the rest here:
Probiotics for the reef - Thegardenisland.com

Direct to Consumer (DTC) Genetic Testing Market Size was valued around USD 800 million in 2018 and is expected to witness lucrative growth from 2019 to 2025.

Rising adoption of genetic tests in various applications including cancer and various genetic disorders will augment the growth of direct to consumer genetic testing market over the forecast period. Currently developed DTC genetic tests allows customer to recognize chance of acquiring a genetic disease. Thus, growing adoption of DTC genetic testing for premature disease detection and identification of genetic diseases will boost the market growth over forecast timeline. However, the genetic tests are costly which may restrict the genetic testing market over forecast period.

Download the sample report to understand the market growth in Direct to Consume Genetic Testing :

https://www.insidemarketreports.com/sample-request/9/152718/direct-to-consumer-genetic-testing-markets

On the basis of test type the market is segregated into predictive testing, carrier testing, Ancestry & relationship testing, nutrigenomic testing and others. Predictive testing has potential to identify complicated disease which might be associated with the patient in future. Thus predictive testing can help in identifying the diseases ahead of time and suggest personalized medicine which aids to segmental growth of predictive testing market over the future.

Genetic testing market by technology is further divided into Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, Whole Genome Sequencing (WGS). Targeted analysis is used to determine the defect in genes that are responsible for a particular disease. Targeted genotyping can precisely determine a persons genetic pool that encodes vital information regarding various disorders. Targeted analysis is less costly compared to rest of the test which will drive the adoption rate of this segment.

North America is anticipated to account for the largest share of the Global Genetic Testing Market. Increasing innovative technologies in genetic tests coupled with rising adoption of these tests will augment the growth of the market. Asia-Pacific is expected to show rapid growth in coming years. Increasing prevalence of chronic diseases will boost the APAC genetic testing market in forecast period.

By Test type

By Application

By Region

Company Coverage

Questions addressed in the report

Conclusion:

In this report, we had discussed the market situation of Direct to Consume Genetic Testing. As we know the world is going to be tech savvy, the demand of trending products and technologies is also increasing. This report can help to understand the business growth in the Direct to Consume Genetic Testing and new opportunities at new places.

Dont push the river; let the river flow!!

Hurry up! and grab the discount for this report

https://www.insidemarketreports.com/discount/9/152718/direct-to-consumer-genetic-testing-markets

For any type of research report, Contact us at:

Company Name: Inside Market Reports

Address: 1 Apache Way, Westford, Massachusetts 01886, USA

Email: [emailprotected]

Contact no: +1-617-230-0741

Follow this link:
Direct to Consumer (DTC) Genetic Testing Market Analysis, Evolving Opportunities, Industry Trends, Business Growth, Revenue And Forecast upto 2025 -...

OKLAHOMA CITY, June 3, 2020 /PRNewswire/ --Progentec, a leader in next-gen diagnostics and digital technologies for the management of autoimmune diseases, announced today that Hakan Sakul, Ph.D., Vice President and Head of Diagnostics at Pfizer, has joined the Progentec Board of Directors. Dr. Sakul has a distinguished track record in the development and commercialization of companion diagnostics, precision medicine, and pharmacogenomics. His wealth of experience and knowledge will support Progentec in its mission to improve health outcomes for people living with autoimmune diseases.

"Lupus is a difficult disease to diagnose and a lab-based testing is sorely needed to confirm its diagnosis," said Dr. Sakul. "I am delighted to join Progentec's Board in this important phase of the company's diagnostics development journey."

In addition to his R&D, clinical, and product expertise, Dr. Sakul has deep experience in regulatory policy. He is currently a member of California Gov. Newsom's Precision Medicine Advisory Council, and was previously an Advisory Board member for California Gov. Brown's Precision Medicine Advisory Committee. Dr. Sakul is also on the board of directors for the Personalized Medicine Coalition and serves on Luminex Corporation's Oncology Advisory Committee.

About Progentec Diagnostics, Inc.

Progentec is committed to improving access and health outcomes for patients in therapeutic areas with a high level of unmet need by combining clinically-validated diagnostic interventions with state-of-the-art digital technologies. Through collaborations with research institutions and health practitioners around the world, Progentec is working to reduce mortality and morbidity while improving care management and service delivery for chronic health conditions.

Forward-Looking Statements:

Statements contained herein that are not historical facts are forward-looking statements that represent management's beliefs and assumptions as of the date of this news release based on currently available information. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements.

Contact:

Mohan Purushothaman

(973) 885-5242

[emailprotected]

SOURCE Progentec Diagnostics, Inc.

http://www.progentec.com

More here:
Precision Medicine and Diagnostics Expert Hakan Sakul, Ph.D., of Pfizer Joins the Progentec Board of Directors - PRNewswire

Fasten your seatbelts, folks, because the stock market has been on one heck of an emotional roller-coaster over much of the past four months. Initially, panic and uncertainty tied to the coronavirus disease 2019 (COVID-19) pandemic sent the broad-based S&P 500 down 34% in less than five weeks. But in the subsequent 11 weeks, we've witnessed roughly 80% of this initial drop clawed back by equities, with Wall Street appearing to enter a new bull market.

Although swoons in the stock market are inevitable, history has decisively shown that opportunistic long-term investors who buy during these periods of weakness tend to make money. It's never really a question of whether you should invest when a new bull market emerges, but where you should park your capital.

Assuming a new bull market has been established, the following four industries look set to thrive (and dominate) for a long time to come.

Image source: Getty Images.

One of the bigger beneficiaries of the COVID-19 pandemic is cybersecurity. To be perfectly clear, cybersecurity was already growing at a healthy pace well before the coronavirus shut down nonessential businesses across much of the country. But with more employees being forced to work remotely than ever before, the need to secure cloud-based data is taking on added importance. Essentially, COVID-19 took an existing trend and gave it a shot of adrenaline.

Hands down, my favorite company in this space is Palo Alto Networks (NYSE:PANW), which I pegged on April 9, 2020, as one of five stocks that could be a 10-bagger (i.e., deliver 1,000%-plus returns) by 2030.

Aside from the fact that enterprise cloud demand continues to pick up, Palo Alto benefits from the fact that it's pushing subscription and support-based solutionsas opposed to hardware. Subscriptions generate much better margins than hardware, and cash flow is far more predictable as Palo Alto is unlikely to see customer churn for what's effectively a basic-need service for any business.

Over the past year, Palo Alto's subscription and support revenue has grown to account for 68% of total sales, up from approximately 62% in the prior-year quarter.

Image source: Getty Images.

Building off of cybersecurity, the hottest thing since sliced bread in the new bull market is going to be anything having to do with cloud computing. This could mean the infrastructure players that are responsible for aiding businesses in creating their cloud, platform-as-a-service providers that allow enterprises to build, manage, and deploy applications, and software-as-a-service companies, which operate and sell ready-to-use apps for businesses and consumers.

Interestingly, some of the most prominent names in the cloud space are the United States' largest publicly traded companies: Amazon (NASDAQ:AMZN) with Amazon Web Services (AWS), Microsoft with Azure, and Alphabet with Google Cloud.

I don't see how investors can't get excited about Amazon in the new bull market. Even putting aside its e-commerce dominance, AWS continues to grow at about twice the pace of its retail/ad operations, and it produces considerably better margins. With Amazon's cloud services now accounting for 13.5% of total sales in Q1 2020 and a majority of its operating income, it's no wonder Wall Street expects a near-tripling in the company's operating cash flow by 2023.

Image source: Getty Images.

The new bull market will also feature an ongoing push toward personalized medicine. By personalized medicine, I'm referring to the idea of tailoring treatment for each individual rather than offering generalized medical solutions. Most personalized medicine leans on the increased use of technology, the cloud, and innovative new devices.

For example, another 10-bagger stock I singled out in April is Livongo Health (NASDAQ:LVGO), a provider of personalized health solutions. Using mountains of collected data and artificial intelligence, Livongo sends tips to members with diabetes in order to help them make meaningful behavioral changes that result in them living longer and healthier lives. It also doesn't hurt that Livongo's solutions can potentially work hand in hand with other wireless diabetes devices (e.g., insulin pumps), meaning patients don't have to leave the comfort of their homes to convey sensitive data to their physicians.

Maybe the best thing about Livongo Health and the personalized medicine push is that it's not all talk. Livongo's Diabetes member count doubled from the prior-year quarter to more than 328,000, and it's already generated two consecutive quarters of profitability despite significant reinvestment into its solutions.

If Livongo is already turning the corner to profitability with less than 1% of U.S. diabetes market share, just imagine its potential when it expands to treat other chronic illnesses, like hypertension.

Image source: Getty Images.

Finally, look for the Internet of Things (IoT) to finally realize its full potential in the new bull market. By IoT, I'm talking about wireless devices being able to connect and communicate with one another and data centers. Examples might include a smart thermostat that learns your heating and cooling preferences to conserve energy usage in your home, or an automobile that automatically reorders a defective or soon-to-be-defective component.

It's not uncommon for Wall Street and investors to overestimate the impact of new technology and be left disappointed. This is sort of what happened with IoT stocks in the latter half of the 2010s. But with an increased reliance on work-from-home, the cloud, and even personalized medicine, the value of IoT is rising like never before.

To build off of the previous industry (personalized medicine), DexCom (NASDAQ:DXCM) is the perfect example of IoT in action. Dexcom, which happens to have a deal in place with Livongo Health, is a producer of continuous glucose monitoring devices for diabetics. DexCom's devices can provide patients with real-time blood-glucose levels, communicate with insulin pumps to administer or hold off on the administration of insulin, and aid in producing reports that can be sent to a primary care provider.

IoT has applications in virtually every industry, and the new bull market should showcase that fact.

See the original post:
4 Industries That'll Thrive in the New Bull Market - Motley Fool

New York, June 09, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Humanized Mouse Model Market 2020-2024" - https://www.reportlinker.com/p05048523/?utm_source=GNW Our reports on humanized mouse model market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising focus on preventing the spread of pandemics and innovative applications. In addition, rising focus on preventing the spread of pandemics is anticipated to boost the growth of the market as well. The humanized mouse model market analysis includes product segment and geographic landscapes

The humanized mouse model market is segmented as below: By Product Genetically humanized mouse model Cell-based humanized mouse model

By Geographic Landscapes North America Europe Asia ROW

This study identifies growing adoption of personalized medicine as one of the prime reasons driving the humanized mouse model market growth during the next few years. "The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our humanized mouse model market covers the following areas: Humanized mouse model market sizing Humanized mouse model market forecast Humanized mouse model market industry analysis"

Read the full report: https://www.reportlinker.com/p05048523/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Follow this link:
The Global Humanized Mouse Model Market is expected to grow by $ 74.72 million during 2020-2024 progressing at a CAGR of 12% during the forecast...

The following discussion and analysis should be read together with our unauditedcondensed consolidated financial statements and related notes thereto set forthin this Quarterly Report on Form 10-Q as well as our Annual Report on Form 10-Kfor the year ended December 31, 2019.This Form 10-Q contains "forward-looking statements" that indicate certain risksand uncertainties, many of which are beyond our control. Actual results coulddiffer materially and adversely from those anticipated in such forward-lookingstatements as a result of certain factors, including those set forth below andelsewhere in this report. Important factors that may cause actual results todiffer from projections include: We may not be able to continue operating without additional financing; Current negative operating cash flows; The terms of any further financing, which may be highly dilutive and may include onerous terms; Significant debt repayments due between June and September 2020, which the Company will likely need to extend or

restructure, with

associated with

pandemic, which

Our precision medicine business, conducted in our Helomics division, iscommitted to improving the effectiveness of cancer therapy using ourproprietary, multi-omic tumor profiling platform, one-of-a-kind database ofhistorical tumor data, and the power of AI to build predictive models of tumordrug response.

Contract Research Organization (CRO) and AI-Driven Business

Patient enrichment & selection for trials

Clinical trial optimization

Via our Helomics subsidiary, we offer a group of clinically relevant,cancer-related tumor profiling and biomarker tests for gynecological cancersthat determine how likely the patient is to respond to various types ofchemotherapy and which therapies might be indicated by relevant tumorbiomarkers.

Skyline Medical - The STREAMWAY System

STREAMWAY System Product Sales

We sell our medical device products directly to hospitals and other medicalfacilities using employed sales representatives, independent contractors anddistributors.

Comparison of three-month periods ended March 31, 2020 and March 31, 2019

Operations expense. Operations expense primarily consists of expenses related toproduct development and prototyping and testing in our current stage.

Liquidity and Capital Resources

Net cash used in operating activities was $2,972,981 and $2,048,653 for thethree months ended March 31, 2020 and March 31, 2019, respectively. Cash used inoperating activities increased in the 2020 period primarily because of theincrease in total operating expense and the additional costs related to theHelomics business.

Liquidity, Plan of Financing, and Going Concern Qualification

We have funded our operations through a combination of debt and equityinstruments including short term borrowings, and a variety of debt and equityofferings.

February 2020 Convertible Note

March 2020 Private Placement of Common Stock and Warrants

March 2020 Amendments to and Extensions of Promissory Notes

April 2020 Paycheck Protection Program

May 2020 Registered Direct Offering of Common Stock and Concurrent PrivatePlacement of Warrants

Off-Balance Sheet Arrangements

We have not engaged in any off-balance sheet activities as defined in Item303(a)(4) of Regulation S-K.

Accounting Standards and Recent Accounting Developments

See Note 1 - Summary of Significant Accounting Policies to the unaudited,Condensed Consolidated Financial Statements of this Quarterly Report on Form10-Q for a discussion of recent accounting developments.

Edgar Online, source Glimpses

Link:
PREDICTIVE ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com

OKLAHOMA CITY, June 3, 2020 /PRNewswire/ --Progentec, a leader in next-gen diagnostics and digital technologies for the management of autoimmune diseases, announced today that Hakan Sakul, Ph.D., Vice President and Head of Diagnostics at Pfizer, has joined the Progentec Board of Directors. Dr. Sakul has a distinguished track record in the development and commercialization of companion diagnostics, precision medicine, and pharmacogenomics. His wealth of experience and knowledge will support Progentec in its mission to improve health outcomes for people living with autoimmune diseases.

"Lupus is a difficult disease to diagnose and a lab-based testing is sorely needed to confirm its diagnosis," said Dr. Sakul. "I am delighted to join Progentec's Board in this important phase of the company's diagnostics development journey."

In addition to his R&D, clinical, and product expertise, Dr. Sakul has deep experience in regulatory policy. He is currently a member of California Gov. Newsom's Precision Medicine Advisory Council, and was previously an Advisory Board member for California Gov. Brown's Precision Medicine Advisory Committee. Dr. Sakul is also on the board of directors for the Personalized Medicine Coalition and serves on Luminex Corporation's Oncology Advisory Committee.

About Progentec Diagnostics, Inc.

Progentec is committed to improving access and health outcomes for patients in therapeutic areas with a high level of unmet need by combining clinically-validated diagnostic interventions with state-of-the-art digital technologies. Through collaborations with research institutions and health practitioners around the world, Progentec is working to reduce mortality and morbidity while improving care management and service delivery for chronic health conditions.

Forward-Looking Statements:

Statements contained herein that are not historical facts are forward-looking statements that represent management's beliefs and assumptions as of the date of this news release based on currently available information. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements.

Contact:

Mohan Purushothaman

(973) 885-5242

mpurushothaman@progentec.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/precision-medicine-and-diagnostics-expert-hakan-sakul-phd-of-pfizer-joins-the-progentec-board-of-directors-301070191.html

SOURCE Progentec Diagnostics, Inc.

Here is the original post:
Precision Medicine and Diagnostics Expert Hakan Sakul, Ph.D., of Pfizer Joins the Progentec Board of Directors - BioSpace

Precision medicine (PM) is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. Personalized nanomedicine involving individualized drug selection and dosage profiling in combination with clinical and molecular biomarkers can ensure the maximal efficacy and safety of the treatment. The major hindrance toward the development of such therapies is the handling of the Big Data, to keep the databases updated. Robust automated data mining tools are being developed to extract information regarding genes, variations, and their association with diseases. Phenotyping, an integral part of PM, is aimed at translating the data generated at cellular and molecular levels into clinically relevant information.Precision Medicine Moves Care from Population-Based Protocols to Truly Individualized Medicine as President of the US announced the Precision Medicine Initiative in his 2015 State of the Union address. Under the initiative, medical care would transition from a one-size-fits-all approach to an individualized approach, in which data on each patients genomic makeup, environment, and lifestyle (the exposome) helps medical professionals tailor treatment and prevention strategies. To achieve the Precision Medicine Initiative mission statement, to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care, researchers and clinicians need vast and varied amounts of data and the technology to ensure that data is widely accessible and usable.

Browse Complete Report with TOC https://univdatos.com/report/precision-medicine-market-current-analysis-and-forecast-2020-2026

Insights Presented in the Report

Based on technology type, the market is fragmented into big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.Recent technological and analytical advances in genomics, have now made it possible to rapidly identify and interpret the genetic variation underlying a single patients disease, thereby providing a window into patient-specific mechanisms that cause or contribute to disease, which could ultimately enable the precise targeting of these mechanisms

Based on the market segment by application type, the market is segmented into oncology, respiratory diseases, central nervous system disorders, immunology, genetic diseases and others. With the advent of precision medicine, cancer treatment is moving from a paradigm in which treatment decision isprimarily based on tumor location and histology followed by molecular information to a new paradigm whereby treatment decisions will be primarily based on molecular information followed by histology and tumor location

Based on the market segment by end-user, the market is fragmented into hospitals & clinics, pharmaceuticals, diagnostic companies, Healthcare-IT firms and others. The precision medicine suppliers that understand technology and the goals of value-based healthcare can create value in the precision medicine value-chain by offering value-based solutions and platforms to interpret and connect data points. There are a number of technology companies who work in the field of precision medicine and more will be founded in the years to come

For better understanding on the market dynamics of Precision Medicine market, detailed analysis was conducted for different countries in the region including North America (United States, Canada, Mexico and Rest of North America), Europe (Germany, UK, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, Australia, India and Rest of APAC), and Rest of World

Some of the major players operating in the market includeHoffmann-La Roche, Medtronic, Qiagen, Illumina, Abbott Laboratories, GE Healthcare, NanoString Technologies, bioMrieux SA, Danaher Corporation, and AstraZeneca

Request for Sample of the report https://univdatos.com/request_form/form/286

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts

The report presents a quick review of overall industry performance at one glance

The report covers in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

Detailed examination of drivers, restraints, key trends and opportunities prevailing in the industry.

Examination of industry attractiveness with the help of Porters Five Forces analysis

The study comprehensively covers the market across different segments

Deep dive regional level analysis of the industry

Feel free to contact us for any queries https://univdatos.com/request_form/form/286

Customization Options:

Precision MedicineMarket can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

About us:

UnivDatos Market Insights (UMI), is a passionate market research firm and a subsidiary of Universal Data Solutions. We believe in delivering insights through Market Intelligence Reports, Customized Business Research, and Primary Research. We are a diverse group of some of the most talented people in the research landscape, who with their collective experience, help us drive our machine and creatively solve every business challenge of millennial organizations. Our team comprises of accomplished professionals from leading consulting environments and serve some of the significant Fortune 500 companies around the world.

Contact us:

UnivDatos Market Insights (UMI)

Email: [emailprotected]

Web: https://univdatos.com

Ph: +91 7838604911

Read this article:
Precision Medicine Market Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020-2026 - 3rd Watch News

Like so many people across the United States and around the world, my colleagues and I at Celmatix feel deeply outraged by the brutal and senseless murders of Breonna Taylor, Ahmaud Arbery, and George Floyd. We stand in solidarity with the millions of people lifting their voices in protest and also join countless more in reflecting on what we can do to make this a turning point for racial inequality.

Inequality comes in many forms for People of Color, both here and abroad, but race-related health disparities are among the starkest and most resistant to progress. Being a Black female further amplifies these inequities, which is particularly troubling and ironic given the fact that Women of Color make up the majority of healthcare workers. Over the last few months, the COVID-19 pandemic has brought this unfortunate reality into even more clear focus.

An often-cited quote in the business world is you cant manage what you cant measure. At Celmatix, we have been working for over a decade to address critical gaps in data collection for womens health. This has included thinking outside of the bubble of traditional research metropolises like Boston and San Francisco, and expanding our research partnerships to reproductive health centers of excellence across the US and to biological repositories that allow us to reach women at community health centers and urban hospitals which serve women who may not have access to reproductive specialist care. In addition to investing in diversified data for our scientific and clinical research studies, weve also made significant investments in our Next Gen Womens Project, an ambitious two-year consumer research effort that interviewed or surveyed more than 4K millennial women to understand how their healthcare needs differ from earlier generations of women and to discern their attitudes concerning their reproductive health and fertility. As part of this research, we had the privilege of collaborating withthe Black Womens Health Imperative, Womens Health Magazine, and Oprah Magazineto better understand why Black women are facing higher infertility rates, greater stigma around reproductive challenges, and larger barriers to accessing fertility care.

Taken together, the picture is clear: the disparities we see in womens health funding, research, delivery, innovation, data collection, and outcomes are consistently amplifiedmultifoldfor women of color.As we reflect on policy changes that could have an outsized impact on addressing centuries of racial inequality in the US, we can think of no better place to start than with improving the health of black women.

Black Womens Health ImperativeThe countrys first nonprofit organization created by Black women to help protect and advance the health and wellness of Black women and girls

Black Mamas Matter AllianceThe alliance helps advocate for better legislation to reduce black maternal mortality, highlights necessary areas of research and spreads information about the social determinants of health that influence outcomes like traumatic birth or maternal and infant mortality.

Sister SongSisterSong is a Southern-based, national membership organization; its purpose is to build an effective network of individuals and organizations to improve institutional policies and systems that impact the reproductive lives of marginalized communities

Fertility for Colored GirlsProvides services for underserved Black women and couples. This includes educational programming about treatment options, resources to connect with counselors, financial grants, and monthly support group meetings hosted by seven different chapters across the country,

Linda Villarosa:Journalist

Patrice Peck:Journalist

Laurie Zephyrin, MD:Obgyn, VP Health Care Delivery System Reform at Commonwealth Fund

Reproductive Injustice: Racism, Pregnancy, and Preterm Birth.Davis DA.NY: NYU Press:

Black Lives Matter: Claiming a Space for Evidence-Based Outrage in Obstetrics and Gynecology.Eichelberger KY, Doll K, Ekpo GE, Zerden ML. Am J Public Health. 2016 Oct;106(10):17712. doi: 10.2105/AJPH.2016.303313.

Key Facts on Health and Health Care by Race and Ethnicity,Samantha Artiga and Kendal Orgera. KFF, Published: Nov 12, 2019

When Maternity Wards in Black Neighborhoods Disappear:NYT, Kelly Glass, May 4, 2020

A Preventable Cancer is on the Rise in Alabama:The New Yorker, Eyal Press, March 30, 2020

This article originally appeared on Celmatix, where Dr.Piraye Yurttas Beim, who is also an EndoFound Board Member, is the founder. If you have additional data to share or organizations you would like us to highlight here, please reach out to atinfo@celmatix.comor info@endofound.org. Please also check back as we plan to expand on this list in the coming weeks. And finally, we urge you to help us raise awareness about this important issue by sharing this in your networks.

See the original post here:
The Disparities In Healthcare For Black Women | EndoFound - Endometriosis Foundation of America - The Blossom

New York, June 05, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Digital Genome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Application ; End User, and Geography" - https://www.reportlinker.com/p05908643/?utm_source=GNW However, dearth of skilled professionals is likely to restraint the growth of the market during the forecast years.

Digital genome is a complete digital set of genetic material that present in an organism or a cell.Digital genome technology deals with genes and their functions to find the causes behind the chronic diseases and also to fix them.

The technology is associated with the advancements that help to make healthcare more personal and more effective for the treatment.Digital genome facilitates instant access to trait sequences to resolve unending custom queries.

Genomic sequencing is rapidly transitioning into clinical practice, and implementation into healthcare systems has been supported by substantial government investment, accounting for US$ 4 billion in at least 14 countries. These national genomic medicine initiatives are driving transformative change under real-life conditions while simultaneously addressing barriers to implement and gather evidence for broader adoption.

The UK has announced the worlds largest genome project as part of 200 million public-private collaboration between charities and pharmaceutical.The UK has already developed the largest genome database in the world through the 100,000 Genomes Project.

Led by Innovate UK as part of UK Research and Innovation, the project will fund researchers and industry to combine data and real-world evidence from UK health services and create new products and services that diagnose diseases efficiently. Moreover, in August 2018, Boston, a Massachusetts-based company, announced that it landed US$ 4.3 million in seed funding and that it would be partnering with Veritas Genetics, a genome sequencing company. The funds will support the companys mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.

Cardiovascular diseases (CVDs) such as atherosclerosis, angina pectoris, and acute myocardial infarction are a significant cause for mortality in the world owing to the present day hectic lifestyle. As per the data provided by WHO, CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can lead to various complications in different parts of the body and can increase the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As there is a significant increase in diabetes cases across the world, it results in life-changing complications among the population. According to the International Diabetes Federation (IDF), in 2017, 46 million diabetic patients were reported in North America, which is expected to reach 62 million in 2045. As chronic diseases are increasing at a faster pace, the research on genomics for life-threatening illnesses has progressed rapidly over the last five years, thereby driving the market growth during the forecast period.

Based on product, the digital genome market is segmented into DNA/RNA analysis, sequencing chips, sequencing and analyzer instruments, sample prep instruments, and sequencing and analysis software. The sequencing and analyzer instruments segment held the largest share of the market in 2019; whereas, the sequencing chips segment is estimated to register the highest CAGR in the market during the forecast period.

Based on application, the digital genome market is segmented into diagnostics, agricultural, academic research, drug discovery, personalized medicine, and other applications. The diagnostics segment held the largest share of the market in 2019; however, personalized medicine segment is estimated to register the highest CAGR in the market during the forecast period.

Based on end user, the global digital genome market is segmented into diagnostics and forensic labs, academic research institutes, hospitals, and others. The diagnostics and forensic labs segment held the highest share of the market in 2019; whereas, the academic research institutes segment is estimated to register the highest CAGR in the market during the forecast period.

The World Health Organization (WHO), Food and Drug Administration (FDA), NHS (National Health Service), and Centers for Disease Control and Prevention are some of the major primary and secondary sources referred for preparing this report.Read the full report: https://www.reportlinker.com/p05908643/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the article here:
Digital Genome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Application ; End User, and Geography - GlobeNewswire

This Patch article is sponsored by Summit Physical Therapy Inc.

Summit Physical Therapy, founded in 1988, is an independent, physical therapist-owned, private practice with a convenient location serving Union, Essex and Morris counties. In a world of medicine dictated by corporations, Summit Physical Therapy stays true to its roots with treatment provided only by licensed physical therapists.

In this environment, it is able to provide the personalized treatment that every patient deserves, as well as develop relationships that last longer than treatment. From exercising to stretching, the practice teaches you exactly how to manage your condition so you can live a happy and pain-free life.

John V. Scioscia, president of Summit Physical Therapy, let Patch in on the secrets to his 30-plus years of success in the business, as well as how the practice is providing virtual treatment throughout the COVID-19 pandemic.

Patch: How long have you been doing business in town?

Scioscia: Summit Physical Therapy has been operating since 1988. My wife and I have lived in Summit now for the past 35 years. We raised our children here and have stuck around even after they left. The whole family has been very involved in the community, between sports, my involvement in various boards and organizations, and my wife previously working at Lincoln-Hubbard Elementary School.

Patch: What attracted you to the line of work you're in, and how did you get started?

Scioscia: I have always had a passion for science and fixing things. As a child, this led me in the direction of medicine. I eventually wound up being recruited to Boston University for wrestling with the intention to become a physician. Over the course of my athletic career at Boston, I became involved with physical therapy and athletic training. After college, I started my career in professional sports, but I soon realized I wanted a life that allowed for more time at home with my family. I founded Summit Physical Therapy, and the rest has been amazing.

Patch: If you had to sum up your business mission in five words to a stranger, what would those words be?

Scioscia: Honest. Independent. Experienced. Skilled. Community.

Patch: What's the most satisfying part of your job?

Scioscia: In general, the most satisfying part of my job is helping people. There are some instances when a patient is dealing with a more difficult or complex case and confides that we have made a breakthrough. That is a special moment. As a physical therapist, I get a lot of time to truly invest in a patient's well-being. Making that personal connection and building trust with someone who needs it most is particularly satisfying.

Patch: How would you say your business or organization distinguishes itself from the others?

Scioscia: The physical therapy industry as a whole has changed in recent years. Most have adopted a "team" model, where your care is delivered by numerous aides, technicians and assistants, putting the therapist in more of a supervisory role. At Summit Physical Therapy, your care is delivered entirely by physical therapists. We pride ourselves in being involved in every part of the rehab process. We even take care of sanitizing surfaces ourselves. Nothing is outsourced. Neighbors caring for neighbors. We have also maintained the same staff. Aside from bringing on a new therapist two years ago, our entire staff has worked here for over 20 years. It is hard to say that about any company, let alone a PT clinic. You definitely know someone who has been treated by our therapists.

Patch: What's the best piece of advice you've ever been given when it comes to success?

Scioscia: "You are either moving forward or moving backward." This has applied to how we manage the business but is also applicable to our patients and athletes.

Patch: Are there any new projects or endeavors you're working on that you're extra excited about?

Scioscia: Interestingly enough, we had been planning to start offering telehealth services starting the summer of 2020 prior to this COVID-19 outbreak. Our goals were to provide an easier way for patients to receive care when they could only make it to the clinic on a less-than-optimal basis, provide PT for our patients who travel for business or vacation, provide a more-efficient method to monitor patients as they phase back into normal life after rehab, and to provide athletic program monitoring from a far with our Performance Therapy service.

Obviously, this pandemic moved our rollout date up by a few months, and we have now been practicing telehealth for over three months! Maintaining our theme of honesty, telehealth is not adequate to replace all in-clinic treatment, but is phenomenal for many treatments. We have seen great success with getting patients in for isolated treatments, if in acute or recent-onset pain, progressing to telehealth when symptoms are less irritable. For patients who are in lesser levels of pain, telehealth can be a great option even to start. We are currently offering free telehealth consultations to answer any questions and to help you find what treatment option is best for you.

Patch: Do you have any events coming up in your community?

Scioscia: In November 2019, we started hosting a lecture series at our clinic as well at a few local businesses. Since March, we have converted the series to webinars, which is not only awesome to maintain social distance but allows many more people to access the information from their home. Keep an eye on our Facebook and Instagram for the next webinar we host.

Patch: How can Patch readers learn more about your work and business?

Scioscia: Our website was designed less as a marketing tool and more as a source of information for our patients and the public. We have information on specific conditions, what to expect with PT page, therapist bios, and even a request for an appointment function. We are also on Facebook and Instagram.

Phone: 908-598-9009Email: physicaltherapysummit@gmail.com

More:
Summit Physical Therapy Offers Personalized Treatment To Patients - Patch.com